

**Texas A&M University-Corpus Christi, Institutional Biosafety Committee
Meeting Minutes**

Meeting Date: 07/25/2025 **Meeting Time:** 2:00 PM
Meeting Location: [REDACTED]

Call to Order:

The Texas A&M University-Corpus Christi, Institutional Biosafety Committee (IBC) met on 07/25/2025 [REDACTED].

The quorum required is 4. There were 7 voting members and 2 non-voting members present at the start of the meeting. Quorum was confirmed.

The meeting was called to order at 2:00 PM.

The meeting minutes will be posted publicly per the National Institutes of Health (NIH) OSP requirement NOT-OD-25-082. All information on matters not covered by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules will be redacted.

Meeting Attendance:

Meeting Chair: Patrick Larkin, Ph.D.

Voting Full Board Members:

Name	Scientific Status	Affiliation Status	Attended by Teleconference?
Patrick Larkin, Ph.D. (Chair)	Scientific, rDNA expert	Affiliated	No
Erica Filep, Ph.D. (Vice Chair)	Scientific, Kinesiology	Affiliated	Yes
Jeffrey Turner, Ph.D.	Scientific, rDNA Expert and Animal Expert	Affiliated	Yes
Jonda Halcomb, Ph.D.	Scientific, Community Member	Non-affiliated	Yes
Yessenia Morris, B.S.	Scientific, Community Member and Animal Expert	Non-affiliated	Yes
Lee Lehman, M.S.	Scientific, Plant Expert	Affiliated	Yes

Voting Alternate Members:

Name	Scientific Status	Affiliation Status	Attended by Teleconference?
Alfred Sustaita, Jr., B.S. (for H. Kumar)	Scientific, EHS	Affiliated	Yes

Non-voting Members in Attendance:

Name	Scientific Status	Affiliation Status	Attended by Teleconference?
Boram Lim, Ph.D.	Scientific, Kinesiology	Affiliated	Yes
Mary Mantle, R.EEG T, REP T. CMEG	Scientific, Community Member	Non-affiliated	Yes

Members attending by teleconference were confirmed as able to actively participate.

Full Board Members Absent: Harshkumar Bhakta, MSc

IBC Staff: John Scarpa, PhD

Guests: None.

I. Conflict of Interest

Members are reminded to disclose any conflict of interest related to any of the items on the agenda. The Chair called for any disclosures of conflict of interest. No conflicts were declared.

II. Minutes

Minutes from the June 20, 2025, meeting were reviewed.

The Chair invited additional comments, questions, and/or concerns. Hearing no further discussion, the motion to approve the meeting minutes was made, seconded, and carried.

Vote Count	Vote Type	Comments
7	For	
0	Against	
0	Abstain	
0	Conflict of Interest	
0	Not present for Vote	

III. Old Business

A) Federal Directive on posting meeting minutes per NOT-OD-25-082: As noted at last meeting, approved meeting minutes from June 1, 2025, will now be posted on the TAMU-CC, IBC website. They will be redacted as allowed, primarily redacting information on items discussing non-recombinant and synthetic nucleic acid molecules. The redacted version will be checked to ensure URL are not still active before posting on website. The Coordinator noted that a sentence (This incident is not reportable to NIH OSP) should be added to the June 20, 2025, meeting minutes after the voting block in the Reportable Incident section as the incident did not involve recombinant or synthetic nucleic acid molecules. Committee voiced no concerns with this suggested edit.

The Chair invited additional comments, questions, and/or concerns. Hearing no further discussion, the motion to approve the edited June 20, 2025, meeting minutes was made, seconded, and carried.

Vote Count	Vote Type	Comments
7	For	
0	Against	
0	Abstain	
0	Conflict of Interest	
0	Not present for Vote	

[REDACTED]

IV. New Business

Chair: No items.

Education: No items.

EHS: No items.

Other:

A) [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	

■		
■		
■		
■		

■		
■		
■		
■		
■		
■		

B)

V. New Studies

None.

VI. Tabled Studies

None.

VII. De Novo Reviews

None.

VIII. Annual Reviews

IBC Number:

TAMU-CC-IBC-2023-0020

Protocol Title:

Bioimaging-based methods for studying the antibacterial mechanism of ionic silver and nanosilver

Principal Investigator:

Pavel, Ioana, PhD

Primary Reviewers:

Jeffrey Turner, PhD and Harshkumar Bhakta, MSc

Conflict of Interest:

None.

The main goal of this research is to develop bioimaging-based methods for studying the antibacterial mechanism of ionic silver (Ag⁺) and nanosilver such as silver nanoparticles (AgNPs).

It is important to study these mechanisms for several reasons:

1. Bioimaging allows researchers to visualize the interaction and localization of silver ions and nanoparticles within bacterial cells or on bacterial surfaces. This helps to understand how silver species interact with bacterial components and where they are located, providing insights into their mechanisms of action.

2. Bioimaging can reveal the specific sites and processes targeted by silver species within bacterial cells. For example, it can help determine whether silver disrupts cell membranes, interferes with intracellular processes, or affects specific organelles. This information is crucial for understanding the underlying antibacterial mechanisms and designing effective antibacterial agents.

3. Bioimaging enables real-time monitoring of the antibacterial process. Researchers can track changes in bacterial morphology, viability, and behavior over time in response to silver treatment. This dynamic information is valuable for elucidating the kinetics and dynamics of antibacterial activity.

4. Bioimaging-based methods can help quantify the extent of silver uptake by bacterial cells, human cells, and tissues. This information is essential for determining optimal dosages that effectively inhibit bacterial growth without causing excessive toxicity to human cells or the environment.

5. Bioimaging can shed light on how bacteria develop resistance to silver species. By visualizing the interactions between silver and bacterial cells, researchers can identify potential mechanisms of resistance.

Lay Summary:**Biohazardous Agents:**

Human Cell Lines, Human blood, Vibrio bacteria, Pseudomonas bacteria, Escherichia coli (non-pathogenic), and BL21(DE3)pLysS Competent Cells

NIH Guidelines:

II-A-3: Use of human cells/cell lines or tissues (e.g. human blood, 293 cell lines, CSF), III-E, III-F: Generation or use of cDNA/genomic libraries, III-F: Use of recombinant or synthetic nucleic acid molecules for detection (e.g. probes)

Submission Type:

Research Protocol

Biosafety Level:

BSL-2

Annual Expiration Date:

09/20/2025

Permit Expiration Date:

09/28/2026

Reviewers had no issues. All personnel are current on training. Biohazardous agents being used have not changed. Environmental and personnel risks from agents are mitigated. Committee had no questions or concerns.

Criteria for approval: The IBC determined that the criteria for approval continue to be met.

The Chair invited additional comments, questions, and/or concerns. Hearing no further discussion, the motion to approve the continuation of the study with a review period of one (1) year was made, seconded, and carried.

[REDACTED]

[REDACTED]

XIII. Miscellaneous

None.

XIV. Closing Comments

[REDACTED]

The meeting was adjourned at 2:55 PM.